Sugi Predict

Sugi Predict / Compounds / SCHEMBL1286875

SCHEMBL1286875

SCHEMBL1286875

CCC=CCCCCC(=O)NCc1ccc(O)c(OC)c1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 8/20 0.85
▸ CYP1A2 P05177 4/20 0.85
▸ CYP3A4 P08684 4/20 0.85
▸ MAPT P10636 3/20 0.85
▸ HPGD P15428 3/20 0.85
▸ CYP2D6 P10635 3/20 0.85
▸ MEN1 O00255 2/20 0.85
▸ TP53 P04637 2/20 0.85
▸ KMT2A Q03164 2/20 0.85
▸ MTOR P42345 1/20 0.85
▸ ALDH1A1 P00352 4/20 0.80
▸ ALOX15 P16050 2/20 0.78
▸ CYP2C9 P11712 2/20 0.78
▸ CYP2C19 P33261 2/20 0.78
▸ KDM1A O60341 1/20 0.78
▸ NR1I2 O75469 1/20 0.78
▸ LMNA P02545 1/20 0.78
▸ ALOX5 P09917 1/20 0.78
▸ ADORA3 P0DMS8 1/20 0.78
▸ PTGS1 P23219 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1286874 1.00 TRPV1 (0.85) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL31010737 1.00 TRPV1 (0.85) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL27205211 0.99 TRPV1 (0.88) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL1586354 0.99 TRPV1 (0.88) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL8154574 0.97 TRPV1 (0.84) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL10407917 0.97 TRPV1 (0.84) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL10543855 0.97 TRPV1 (0.84) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL12313044 0.93 TRPV1 (0.89) TRPV1CYP1A2CYP3A4MAPTHPGD
Olvanil SCHEMBL537603 0.92 TRPV1 (1.00) TRPV1CYP1A2CYP3A4MAPTHPGD
SCHEMBL10711239 0.92 TRPV1 (0.96) TRPV1CYP1A2CYP3A4MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115335358-B Synthesis of Capsaicin Derivatives 阿克西赫姆公司 2024-07-12 — — CN disclosed
EP-4263495-A1 PHARMACEUTICAL FORMULATIONS OF A PHENOLIC TRPV1 AGONIST PRODRUG Concentric Analgesics, Inc. (US) 2023-10-25 — — EP disclosed
EP-4259136-A1 CRYSTALLINE FORM OF A PHENOLIC TRPV1 AGONIST PRODRUG Concentric Analgesics, Inc. (US) 2023-10-18 — — EP disclosed
WO-2022132649-A1 PHARMACEUTICAL FORMULATIONS OF A PHENOLIC TRPV1 AGONIST PRODRUG Concentric Analgesics, Inc. (US) 2022-06-23 — — WO disclosed
WO-2022132646-A1 CRYSTALLINE FORM OF A PHENOLIC TRPV1 AGONIST PRODRUG Concentric Analgesics, Inc. (US) 2022-06-23 — — WO disclosed
EP-3830078-A1 PEGYLATED PRODRUGS OF PHENOLIC TRPV1 AGONISTS Concentric Analgesics, Inc. (US) 2021-06-09 — — EP disclosed
WO-2021063373-A1 TRPV1 AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF 南京清普生物科技有限公司 2021-04-08 — — WO disclosed
WO-2021035037-A1 METHOD TO INCREASE SYSTEMIC BLOOD PRESSURE IN SHOCK GEORGETOWN UNIVERSITY (US) 2021-02-25 — — WO disclosed
WO-2020023794-A1 PEGYLATED PRODRUGS OF PHENOLIC TRPV1 AGONISTS Concentric Analgesics, Inc. (US) 2020-01-30 — — WO disclosed
CN-109562281-A Prodrugs of phenolic TRPV1 agonists for use in combination with local anesthetics and vasoconstrictors for improving local anesthesia 同心镇痛药物公司 2019-04-02 — — CN disclosed
WO-2015193371-A1 IMPROVED SELECTIVITY OF THE PRODUCTION OF VANILLOIDS IN A RECOMBINANT UNICELLULAR HOST RHODIA OPERATIONS (FR) 2015-12-23 — — WO disclosed
US-20150216955-A1 IMMUNOMODULATORY AGENT AND USES THEREFOR THE UNIVERSITY OF QUEENSLAND (AU) 2015-08-06 — — US disclosed
US-20150202285-A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES THE UNIVERSITY OF QUEENSLAND (AU) 2015-07-23 — — US disclosed
US-9017697-B2 Compositions and methods for modulating immune responses THE UNIVERSITY OF QUEENSLAND (AU) 2015-04-28 — — US disclosed
WO-2014159884-A1 APPLICATION OF ENCAPSULATED CAPSAICIN AND ANALOGUES THEREOF FOR CONTROLLING CALORIE INTAKE Altria Client Services Inc. (US) 2014-10-02 — — WO disclosed
CN-102089277-B Cyclic amine-1-carboxylic acid ester derivative and pharmaceutical composition containing same DAINIPPON SUMITOMO PHARMA CO 2014-02-12 — — CN disclosed
WO-2011138565-A1 PHARMACEUTICAL COMBINATION CONTAINING LIPOIC ACID, HYDROXYCITRIC ACID AND A SOMATOSTATIN AS ACTIVE INGREDIENTS BIOREBUS (FR) 2011-11-10 — — WO disclosed
US-20100151000-A1 COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES THE UNIVERSITY OF QUEENSLAND (AU) 2010-06-17 — — US disclosed
EP-1660481-A1 PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2006-05-31 — — EP disclosed
WO-2005016915-A1 PIPERIDINE/CYCLOHEXANE CARBOXAMIDE DERIVATIVES FOR USE AS VANILLOID RECEPTOR MODULATORS GLAXO GROUP LIMITED (GB) 2005-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150216955-A1 IMMUNOMODULATORY AGENT AND USES THEREFOR HLA-DRB1, CD74, CHI3L1 TRPV1 2861/4885CYP1A2 4612/4885CYP3A4 4654/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.